Under the terms of the Agreement and subject to applicable law, Geron will distribute the Asterias Series A common stock received from Asterias to Geron`s stockholders on a pro rata basis (the "Series A Distribution"), other than with respect to fractional shares and stockholders in certain to-be-determined excluded jurisdictions, who will instead receive cash on a pro rata basis. To initiate the Series A Distribution, Geron will set a record date, following notice from BioTime and Asterias that certain securities registration or qualification requirements have been met. Only Geron stockholders as of that record date will be eligible to participate in the Series A Distribution. Following the Series A Distribution to Geron`s stockholders, Asterias will then distribute the BioTime Warrants on a pro rata basis to the holders of Asterias Series A common stock. Further information about the Series A Distribution and the BioTime Warrants distribution will be available upon the record date, which is expected to occur within the next sixty days. A public announcement regarding the record date is expected to occur at least ten days prior to the record date.
You didn't mention the part of the 8-K that reveals how Geron might not be able to distribute the Asterias Series A stock or warrants ......nor did you tell about the part of the 8-K stating the Series A stock and warrants might have no value should a distribution take place......nor did you mention the 8-K statement explaining there is no market in which to trade the Asterias Series A shares.
We longs dislike perpetual shorts but Maine could be right. Currently the distribution has no market value and although it seems unlikely that neither the Class A common nor the warrants trade, it is possible that they will have no value.
You are right maine ... My GOD look at these !!!!!!!!!
Investment in new business strategies and acquisitions could disrupt the Company’s ongoing business and present risks not originally contemplated.
The Company is subject to laws and regulations, changes to which could increase the Company’s costs and individually or in the aggregate adversely affect the Company’s business.
The Company’s stock price is subject to volatility.
The Company could be impacted by unfavorable results of legal proceedings.
These statements are based on management's best assumptions and beliefs in light of the information currently available to it. Because they involve risks and uncertainties, actual results may differ materially from the results that we currently expect. Factors, including risks and uncertainties that could cause these differences include, but are not limited to:
the inability to close the Sale of the_____Business in a timely manner, or at all, for instance due to the inability or delays in obtaining the shareholder approval or necessary regulatory approvals for the Sale of the ____ Business,
the implementation of the Sale of the ___ Business, including our internal reorganization in connection therewith, which will require significant time, attention and resources of our senior management and others within the company potentially diverting their attention from other aspects of our business;
disruption and dissatisfaction among employees caused by the plans and implementation of the Sale of the ____ Business reducing focus and productivity in areas of our business;
the amount of the costs, fees, expenses and charges related to or triggered by the Sale of the D&S
any impairments or charges to carrying values of assets or liabilities related to or triggered by the Sale of the ____ Business
These disclaimers are from Apple, Microsoft, and Nokia found on their SEC forms.
EVERY Business gives the worst Case Scenario and Geron is NO different.